Type “nootropic” into any supplement store search bar and you’ll find creatine sitting next to racetams, mushroom extracts, and choline donors, as if it belonged to the same family all along. It doesn’t, at least not in any straightforward way, and the reasons why are more interesting than the marketing suggests.
Here is the short answer. Creatine can reasonably be called a nootropic under the loose modern definition, which covers anything taken to support cognitive performance. Under the original, stricter definition, and more importantly under the actual weight of the evidence, the label fits awkwardly. Creatine is not a focus pill and it does not work the way most nootropics claim to. It is an energy buffer that the brain builds up slowly over weeks, and its measurable cognitive effects so far are modest, domain specific, and concentrated in particular groups of people and particular stressed conditions. The largest trial ever run on the question found effects so small they bordered on nothing, and Europe’s food safety regulator looked at the whole file in 2024 and declined to endorse a cognition claim. If you’re asking whether creatine is a nootropic, the honest answer is that it’s something stranger and slower than that word usually implies.
Let’s take it apart properly.
What the Word Nootropic Actually Means
The term was coined in 1972 by the Romanian chemist and psychologist Corneliu Giurgea, the man who synthesized piracetam. Giurgea did not mean “anything that helps you think.” He laid out specific criteria: a true nootropic should enhance learning and memory, help the brain keep functioning under disruptive conditions such as low oxygen, protect the brain against physical and chemical injury, and do all of this with very low toxicity and without the sedation or stimulation typical of psychiatric drugs.
By those criteria, remarkably few substances qualify, and the modern supplement aisle would mostly flunk. Caffeine is a stimulant, so it fails on Giurgea’s own terms. Most botanical “brain boosters” fail on the evidence requirement. Over the decades the word drifted, and today “nootropic” is used commercially for any ingredient with a plausible story about cognition, which is how creatine ended up in the category.
The irony is that creatine arguably comes closer to Giurgea’s original criteria than most products sold under the label. It has one of the best safety records in the entire supplement industry after decades of study in athletes. It is not a stimulant and has no psychoactive kick. And the most consistent signals in the research involve exactly what Giurgea emphasized: helping the brain cope under disruptive conditions, in creatine’s case sleep deprivation and low energy states, rather than making a rested, healthy brain sharper. Whether the human evidence is strong enough to say it enhances memory and learning is the harder question, and we’ll get to it.
Why Creatine Comes Up in Brain Conversations at All
Creatine is a compound your body makes from three amino acids and that you also get from meat and fish. Most of it sits in muscle, but around a fifth of your daily creatine turnover happens in the brain, which is one of the most energy hungry organs you own.
The mechanism story is genuinely good, which is part of why this topic refuses to die. Brain cells run on ATP, the molecule that carries usable energy, and creatine in its phosphorylated form acts as a rapid recharging system for ATP when demand spikes. Think of phosphocreatine as a small backup battery that neurons can draw on faster than they can burn fresh fuel. When researchers stress the brain, whether through demanding cognitive tasks or sleep loss, phosphocreatine levels shift in ways that suggest this buffer is actually being used.
A plausible mechanism is not the same thing as a demonstrated benefit, though, and this is where the field has repeatedly tripped over itself. The history of supplements is full of beautiful mechanisms attached to disappointing trials. So the only question that matters is what happens when you give people creatine and measure their cognition against placebo.
The 2003 Study That Started Everything
The paper that launched creatine’s cognitive reputation came from Caroline Rae’s group in Australia. In a double blind crossover trial published in 2003, 45 young adult vegetarians took 5 grams of creatine daily for six weeks, then switched to placebo, or the reverse. The creatine phase produced large, highly significant improvements on two tests: backward digit span, a working memory task where you repeat number sequences in reverse, and Raven’s Advanced Progressive Matrices, an abstract reasoning test often used as a proxy for fluid intelligence.
The effect sizes were striking, the design was solid for its time, and the press coverage wrote itself. Creatine boosts intelligence. That framing has echoed through supplement marketing for over twenty years.
Two details matter enormously and usually get dropped. First, every participant was vegetarian, chosen deliberately because people who eat no meat get no dietary creatine and tend to have lower stores in muscle and blood. Second, it was one study of 45 people, and single studies with dramatic results have a well documented habit of shrinking when someone tries to repeat them.
The Replication That Complicated the Story
Someone did try to repeat it, properly, and this is the study I wish more people knew about. In 2023, Julia Fabienne Sandkühler and colleagues published the largest trial on creatine and cognition to date in BMC Medicine. It was preregistered, randomized, double blind, placebo controlled, and used a crossover design with 123 healthy adults, including both vegetarians and omnivores. The dose and duration deliberately matched Rae: 5 grams a day for six weeks. So did the primary outcomes, backward digit span and Raven’s matrices.
The result was a nothingburger with a faint aroma of something. The working memory effect only bordered on statistical significance, with a p value of 0.064, and the effect sizes were tiny: a Cohen’s d of 0.09 for the reasoning task and 0.17 for working memory, compared to the large effects Rae reported. There was no significant effect on any of the eight additional exploratory cognitive tasks covering attention, verbal fluency, task switching, and memory. And critically, there was no special advantage for vegetarians, which undercuts the most popular explanation for why the 2003 result was so big.
The authors’ own conclusion was carefully worded: creatine might have a small beneficial effect, and larger studies would be needed to confirm or rule it out. That is a long way from “creatine boosts intelligence,” and it came from a team that designed their study specifically to give the original finding a fair chance.
This is what a maturing evidence base looks like, and it’s worth sitting with. The flashy early result did not exactly fail, but it did not survive at anything like its original size. If you only ever read about Rae 2003, you have a 2003 understanding of this question.
What the Meta Analyses Found, and Where They Wobble
When individual trials disagree, researchers pool them. Creatine and cognition has now been pooled several times, and the pattern across those reviews is honestly messier than any single summary admits.
The most cited recent effort is a 2024 meta analysis by Xu and colleagues in Frontiers in Nutrition, covering 16 randomized controlled trials with 492 participants ranging from their early twenties to their mid seventies, including both healthy people and patients with various conditions. It reported a significant benefit for memory, with a standardized effect size of 0.31, which is small to moderate, plus improvements in attention time and processing speed time. It found no significant effect on overall cognitive function or executive function, the mental skill set covering planning, switching, and self control. Subgroup analyses suggested more benefit in people with illnesses, in adults under 60, and in women.
Before you file that away as the answer, three caveats. First, this paper needed a corrigendum in February 2025 to correct a translation error in its attention results, which is not disqualifying but is a reminder to read the corrected record rather than the headline. Second, and more seriously, when the European Food Safety Authority examined this exact meta analysis in its 2024 assessment, its panel concluded that the analysis had pooled multiple related cognitive tests from the same studies as if they were independent, double counting participants and inflating sample sizes, and that no conclusions could be drawn from it for substantiating a claim. That is about as blunt as regulatory language gets. Third, 492 participants spread across 16 trials and five cognitive domains is simply not a lot of data.
An earlier meta analysis by Prokopidis and colleagues in Nutrition Reviews, published in 2023, focused on memory in healthy people and found that creatine improved memory mainly in older adults aged 66 to 76, with no significant effect in younger adults. That sounds tidy until you learn that the older adult finding rested on just two small studies totaling 57 people, only one of which was positive, and that the Sandkühler team pointed out the analysis had omitted at least one relevant trial that might have changed its conclusions. A 2018 systematic review by Avgerinos and colleagues, covering six trials and 281 people, had reached a similarly hedged verdict: short term memory and reasoning may improve, with effects on other domains unclear and findings mixed.
Then there is the review that supplement marketing pretends does not exist. In 2024, Terry McMorris and colleagues published a systematic review in Behavioural Brain Research whose title says it plainly: creatine supplementation research fails to support the theoretical basis for an effect on cognition. Their reading of the same literature is that supplementation does raise brain creatine content, but only to a limited extent, that results on actual cognitive performance are equivocal, and that the most promising signal is in stressed populations rather than rested healthy people. They also flagged persistent design problems, including supplementation regimens that may be too small to move brain creatine meaningfully, and the strange absence of brain creatine measurement in most cognition trials.
Put the reviews side by side and a fair summary emerges. There is a small, inconsistent signal for memory and processing speed. There is essentially nothing for executive function or global cognition. The subgroup stories contradict each other, with one review finding the benefit in older adults and another finding it in adults under 60. And the single largest, best designed trial found close to nothing. Anyone telling you this question is settled, in either direction, is ahead of the data.
Sleep Deprivation Is a Different Story, With a Big Catch
Now for the finding that generated the most excitement in years, and the one most likely to be misused. In February 2024, Ali Gordji-Nejad and colleagues at Forschungszentrum Jülich in Germany published a study in Scientific Reports showing that a single dose of creatine improved cognitive performance during sleep deprivation. Fifteen healthy young adults stayed awake for 21 hours while researchers tracked their brain chemistry with phosphorus and proton magnetic resonance spectroscopy, imaging methods that measure energy related compounds in living brain tissue, and tested their cognition at baseline and at 3, 5.5, and 7.5 hours after dosing.
Creatine beat placebo on word memory and on processing speed across language, logic, and numeric tasks, and it produced measurable shifts in the brain’s high energy phosphate balance. The team followed up with a 2026 study in Nutrients in 29 subjects using a lower dose of 0.2 grams per kilogram, again during 21 hours of sleep deprivation, and again found that creatine softened the decline in logical and numerical tasks, language related processing speed, and psychomotor vigilance.
Here is the catch, and it is not small. The dose in the original study was 0.35 grams per kilogram of body weight, taken all at once. For an average adult that is roughly 25 grams, about five to eight times the standard daily scoop, and the follow up’s “lower” dose still works out to around 14 grams for a 70 kilogram person. These were single experimental doses given under medical supervision to people being deliberately kept awake in a lab. The researchers themselves were explicit that the whole point of the high dose was to force a temporary increase in brain uptake that normal dosing does not achieve on a short timescale.
So this research does not show that your morning 5 grams will rescue a bad night’s sleep, and it does not show that megadosing creatine at home is a good idea, particularly since the study authors have noted the kidney load such doses could involve. What it shows is that the brain energy mechanism is real enough to detect under extreme conditions, in small samples of young adults, at doses nobody should self prescribe. That is scientifically fascinating and practically limited, and both halves of that sentence deserve equal weight. It also fits the Giurgea theme mentioned earlier, that the clearest creatine signals appear when the brain is under stress, not at baseline.
What Regulators Concluded When They Read Everything
In the United States, creatine is sold as a dietary supplement, which means the FDA does not approve cognitive claims before products reach shelves. Companies can make general structure and function claims about supporting normal body processes, while the FTC requires that advertising claims be substantiated, and no US authority has evaluated or endorsed creatine as a cognitive enhancer. That regulatory quiet is easy to mistake for endorsement. It isn’t one.
Europe runs a stricter system, and it recently produced the closest thing this field has to an independent audit. A company applied to EFSA, the European Food Safety Authority, for permission to claim that creatine improves cognitive function. In its November 2024 opinion, the panel went through the trials one by one, noted that a six week study at 10 or 20 grams a day in 30 healthy young adults by Moriarty and colleagues found no effect on processing speed, episodic memory, or executive function, noted that the large Sandkühler trial found no significant effect on any primary or exploratory endpoint, dismissed the Xu meta analysis for the double counting problem described above, and declined to substantiate the claim.
An EFSA rejection does not bind US products and it does not mean creatine does nothing. Regulators set a deliberately high bar: consistent effects, in the general population, at feasible doses. What the opinion tells you is that when neutral scientists with no product to sell read the complete file in 2024, they did not find that bar cleared. Any honest article on this topic has to carry that fact, and most don’t.
So, Is Creatine a Nootropic?
By the modern marketing definition, sure. People take it hoping for cognitive benefit, some studies support modest effects, and it sits comfortably in the category alongside ingredients with far weaker files.
By the stricter original definition, the picture is genuinely mixed. On safety and tolerability, creatine outperforms almost everything else in the category. On protecting function under disruptive conditions, the sleep deprivation work is a real, if preliminary and high dose, point in its favor. On enhancing memory and learning in healthy rested people, the evidence is thin, inconsistent, and headlined by a large replication that found close to nothing.
But I think the framing itself is the problem, which is why the title of this piece calls creatine a different kind of cognitive supplement. Most things sold as nootropics promise an acute effect: take this, feel sharper within the hour. Creatine, at normal doses, cannot work that way even in principle. The brain takes it up slowly against a steep concentration gradient, through a dedicated transporter, and studies suggest that weeks of standard dosing raise brain creatine by only modest single digit percentages, far less than the roughly 20 percent rise muscle can achieve in under a week. You are not switching anything on. You are, at best, very gradually topping up a buffer whose baseline level varies from person to person.
That reframing explains most of the confusion in this literature. If creatine’s cognitive effect depends on how full your buffer already is, you would expect exactly what we see: bigger apparent effects in people likely to start lower, weak or absent effects in well fed healthy young omnivores, and clearer signals when the brain is stressed hard enough to actually lean on the buffer. Whether that expectation survives better trials is an open question, but it is at least a coherent one, which is more than can be said for “creatine makes you smarter.”
Who Might Plausibly Notice Something, and Who Probably Won’t
If you’re a healthy omnivorous adult sleeping reasonably well, the current evidence gives you little reason to expect a noticeable cognitive change from creatine. The trials that most resemble you, including the Moriarty dose response study and the bulk of the Sandkühler sample, found effects ranging from tiny to absent. Plenty of people in this group take creatine anyway for muscle and strength reasons, where the evidence is far stronger, and treat any brain effect as a possible bonus. That is a defensible way to think about it, as long as the word possible is doing real work.
Vegetarians and vegans occupy a strange middle position. The dietary logic is real, since they consume essentially no creatine, and the original 2003 result came entirely from vegetarians. But the replication found no vegetarian advantage, and interestingly, imaging studies have found that vegetarians’ brain creatine levels look comparable to omnivores’ even when their muscle and blood levels run lower, suggesting the brain defends its own supply through internal synthesis. A separate 2011 study by Benton and Donohoe reported a memory benefit in vegetarian women after about five days at 20 grams daily, though the Sandkühler team cautioned that the large number of cognitive tests in that study made a false positive likely and regarded the finding as exploratory.
Older adults have the Prokopidis result in their favor and biological plausibility on their side, since brain energy metabolism declines with age. They also have the thinnest data: a 2026 systematic review in Nutrition Reviews covering creatine and cognition in older adults found only six relevant studies, described the evidence as sparse despite a generally positive direction for memory and attention, and noted that the two intervention trials it included pointed in different directions. If you are hoping creatine addresses dementia or any other condition, the research is nowhere near supporting that, and nothing here should be read as suggesting otherwise.
The sleep deprived are the group with the newest and most mechanistically direct evidence, and also the group for whom the studied protocol, a single dose of 14 to 25 grams under supervision, least resembles anything you should copy at home.
Whoever you are, if you’re considering creatine for any health reason, talk to your doctor first, especially if you have kidney concerns. And note what the studied material has been in essentially all of this research: plain creatine monohydrate, the cheap unglamorous powder, not any of the premium forms marketed with brain themed branding. The Xu meta analysis made a point of noting that every one of its 16 included trials used monohydrate. In the US that powder typically runs well under a dollar per 5 gram serving from major supplement retailers, which matters here for a simple reason: when a product costs several times more on the strength of a brain claim, you are paying the premium for marketing, not for evidence.
It’s also worth being clear about the gap between what the trials did and what people actually do. The positive cognition studies used sustained daily dosing for four to six weeks or longer, or single supervised megadoses. Taking creatine sporadically, a scoop here when you remember, a skipped week there, matches neither protocol, and given how slowly brain stores change, sporadic use is the pattern least likely to do anything at all.
What Would Change the Picture
This field needs three things, and the researchers within it largely agree. Trials big enough to detect small effects, since a d of 0.1 to 0.2, which is where the honest estimates now sit, requires hundreds of participants to pin down. Trials that actually measure brain creatine before and after, so we stop guessing whether the intervention reached the organ being tested, a gap McMorris and colleagues called essential to close. And systematic dose and duration work in the groups where the buffer hypothesis predicts benefit: people with low baseline stores, older adults, and people under metabolic stress.
Until then, here’s where I land on the question in the title. Is creatine a nootropic? It’s a safe, cheap, genuinely interesting brain energy compound with a mechanism that keeps earning partial vindication and a clinical record that keeps refusing to match the hype. Under sleep deprivation, at experimental doses, it demonstrably props up a flagging brain. At the scoop a day level in healthy people, the best current answer is: probably not much, possibly a small memory effect, and nobody can honestly promise you more. That makes it a poor fit for the nootropic aisle’s marketing and, in my view, a better citizen of it than most of what’s on the shelf. What would change my mind is a large preregistered trial in a low creatine population with brain imaging attached. When that study lands, whatever it finds, you’ll read about it here.